Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 7/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18077656 | 0.90 | PDK2 (0.35) | ABL1PDK2PDK1PDK3 | |
| SCHEMBL16474446 | 0.88 | ABL1 (0.42) | ABL1TRPA1MCHR1NPBWR1 | |
| SCHEMBL16474983 | 0.88 | ABL1 (0.42) | ABL1TRPA1MCHR1NPBWR1 | |
| SCHEMBL16474962 | 0.82 | MAPT (0.38) | TRPA1MCHR1 | |
| SCHEMBL16475022 | 0.82 | ABL1 (0.41) | ABL1TRPA1MCHR1NPBWR1 | |
| SCHEMBL16474961 | 0.81 | ABL1 (0.37) | ABL1TRPA1MCHR1NPBWR1 | |
| SCHEMBL16475063 | 0.81 | ABL1 (0.42) | ABL1TRPA1MCHR1NPBWR1 | |
| SCHEMBL16475018 | 0.80 | ABL1 (0.42) | ABL1TRPA1MCHR1NPBWR1 | |
| SCHEMBL16474940 | 0.80 | ABL1 (0.47) | ABL1PDK2 | |
| SCHEMBL22421237 | 0.80 | ADORA2B (0.39) | ABL1ADORA2BADORA2AADORA1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903991-B1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10544161-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10376497-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2019-05-16 | — | — | US | disclosed |
| US-10233195-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| WO-2015153683-A1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | ABL1 3203/4885PDK2 1258/4885ADORA2B 2395/4885 |
| US-10544161-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | ABL1 3203/4885PDK2 1258/4885ADORA2B 2395/4885 |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | ABL1 3203/4885PDK2 1258/4885ADORA2B 2395/4885 |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | ABL1 3203/4885PDK2 1258/4885ADORA2B 2395/4885 |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | ABL1 3203/4885PDK2 1258/4885ADORA2B 2395/4885 |
| US-10233195-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | ABL1 3203/4885PDK2 1258/4885ADORA2B 2395/4885 |
| US-10376497-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | ABL1 3203/4885PDK2 1258/4885ADORA2B 2395/4885 |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | ABL1 3203/4885PDK2 1258/4885ADORA2B 2395/4885 |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | ABL1 3203/4885PDK2 1258/4885ADORA2B 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.